• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Immutep Shares Hold Steady despite Operational Update (ASX:IMM)

Like 0

By Ryan Clarkson-Ledward, Friday, 07 May 2021

Cancer immunotherapy developer Immutep Ltd [ASX:IMM] share price is trading neutral at time of writing, holding steady after flip-flopping between earlier gains and losses...

Cancer immunotherapy developer Immutep Ltd [ASX:IMM] share price is trading neutral at time of writing, holding steady after flip-flopping between earlier gains and losses.

A sign that perhaps investors are unsure what to make of the company’s latest operational update, despite managements best efforts to no doubt spin a positive angle.

Let’s talk details…

Trials on track, and data on the way

As we’ve talked about previously in Money Morning, Immutep is busy working on their ‘efti’ treatment solution. A novel protein that has shown promising potential to fight against certain cancers.

You can read up all about that in our past coverage, right here.

Right now though, the company is in the midst of working on not one, not two, but four clinical trials. Three of which are in or proceeding to Phase II and one of which is in Phase I.

Of these trials, the most pressing is perhaps the AIPAC trial. A test of efti’s potential to treat metastatic breast cancer.

And as management notes, the trial is on track to report its final overall survival (OS) data in the second half of this year. With roughly 72% of all patients in the trial at the endpoint of testing.

So shareholders should be eagerly awaiting the results of this critical investigation.

On top of that, the TACTI-002 trial looking into non-small cell lung cancer (NSCLC) is also progressing. With Immutep still recruiting new patients for the Phase II Part A trial. As it stands, 54 enrolments out of a possible 110 have been filled.

Meanwhile, a concurrent trial for second-line NSCLC is also recruiting as well, under a Part B test. With 27 out of a possible 36 patients already receiving the first treatment.

As well as the likelihood of Immutep to present new data on TACTI-002 in early June, so keep an eye out for that as well.

Then there is TACTI-003, which is looking into efti’s potential to fight head and neck squamous cell carcinoma (HNSCC). With Immutep currently working on getting a Phase II trial up and running. All they need is approval from the necessary authorities and overseers.

And last but not least, there is INSIGHT-004. A phase I trial that will also report final data in early June as well. The fourth arm in long-standing collaborative effort between Immutep and Merck KGaA, Darmstadt, Pfizer Inc, and Germany.

So, it’s clear as day that this company is gearing up for a big second half to 2021.

With plenty of opportunities for this stock to share a surprise breakthrough that could send its share price soaring…

What’s next for Immutep Share Price?

Looking ahead, this update has mapped out most of the big events ahead of this stock. Meaning investors should largely know when to expect any big developments.

So it’s simply a waiting game to find out whether they will be positive or negative.

For some shareholders, that will certainly be a tantalising prospect. For others, it could leave them fraught with anxiety.

After all, depending on how all these trials unfold, Immutep’s share price will react one way or the other.

And for that reason, it’s a stock that won’t suit every investor.

This is definitely one small-cap that is built for speculators. Which shouldn’t come as much of a surprise given the volatile history of this stock.

Granted, volatility is something that every investor needs to get accustomed to. Just maybe not the extreme kind that Immutep serves up…

But if you’re looking for ways to improve your handling of volatile stocks and markets, we can help.

Our resident trading expert, Murray Dawes, has put together a handy guide on how to help manage your investing risk. Check it out for yourself, for free, right here.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Vicuña: The Greatest Mineral Discovery of Our Lifetime
    By James Cooper

    James Cooper returns to his geologist roots, revealing the industry’s most critical exploration discovery made in decades…The Vicuña District in Argentina.

  • “Green gold”…primed for a comeback!
    By Callum Newman

    Investors always find rare earth shares compelling. There’s something about their mystery, their strategic nature and the geopolitics around the whole industry that the market finds almost irresistible. In 2025, all those reasons are entirely justified. We can see that here…

  • Don’t Get Swept Up By the Herd: Bulls & Bears in an Age of Social Media
    By Charlie Ormond

    Markets have always reflected this chaotic behaviour, but today’s markets operate in an environment fundamentally transformed by social media.

Primary Sidebar

Latest Articles

  • Vicuña: The Greatest Mineral Discovery of Our Lifetime
  • “Green gold”…primed for a comeback!
  • Don’t Get Swept Up By the Herd: Bulls & Bears in an Age of Social Media
  • The latest Closing Bell is available now
  • Thorium: One Step Closer to China’s Energy Fortress

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988